Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert
CEO, Glenn Gilbert
Source: Rhythm Biosciences
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Rhythm Biosciences (RHY) files ColoSTAT with the Australian TGA for listing on the Australian Register of Therapeutic Goods (ARTG)
  • TGA approval is needed for Rhythm and its partners to market and sell ColoSTAT in the Australian market
  • Rhythm expects the review to be completed in three to six months and in the interim will execute key technical, administrative and logistical activities
  • ColoSTAT measures the presence and concentration of protein markers seen in colorectal cancer and determines whether the patient has it or not
  • Rhythm shares are trading steady at $1.21

Rhythm Biosciences (RHY) has filed ColoSTAT with the Australian Therapeutic Goods Administration (TGA) for listing on the Australian Register of Therapeutic Goods (ARTG).

TGA approval is needed for Rhythm and its partners to market and sell ColoSTAT in the Australian market.

With the application filed, the TGA will assess Rhythm’s ARTG submission and key technical documents to provide final approval to enable the commercialisation of ColoSTAT.

Rhythm expects the review to be completed in three to six months and in the interim will execute key technical, administrative and logistical activities.

ColoSTAT is a biochemical test that measures the presence and concentration of multiple protein markers seen in colorectal cancer.

The patient is first recommended for a ColoSTAT test by their doctor, before they give a blood test and the results are analysed.

If it reveals the patient has colorectal cancer then they will go in for a colonoscopy as soon as possible.

“The team continues to diligently execute on our plans as we target ColoSTAT revenues in late CY22,” CEO and Managing Director Glenn Gilbert said.

“We are very close to being in a unique position to transform and revolutionise the colorectal diagnostic market with our lifesaving cancer detection technology.”

Rhythm was trading steady at $1.21 at 2:18 pm AEST.

RHY by the numbers
More From The Market Online
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…